Skip to content
DataLookout
Menu

NCT06177106

SUV PDL1/PD1 in Sun Damaged & Sun Protected Human Skin of Participants

StatusSuspended
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Recruitment suspended Sponsor's reason: Per study team, study will be temporarily suspended with plans to re-open in March 2027.
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  2. Notable Primary completion date: Mar 1, 2025 to Mar 1, 2027
    • Study completion date: Dec 31, 2025 to Dec 31, 2027
    v5
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jan 1, 2024 to Dec 26, 2023
    • Site details revised
    v3
  4. Minor Secondary endpoints: details revised at 1 of 3 entriesv2
  5. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To assess PD-L1 protein expression levels in the epidermal keratinocytes of subjects with and without a history of cutaneous squamous cell skin cancer.
Timeframe: Changes from baseline (pre-SSL exposure) to post-SSL exposure (at 24 hour post-exposure).

Secondary (3)

Evaluation of CD70/CD27 protein expression analysis
Spatial genomic assessment through whole transcriptomic analysis
High dimensional data analysis

Arms and interventions

Cohort A - history of > 2 Cutaneous squamous cell carcinoma (cSCC)Other

Participants who have a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability. Subjects from each cohort will be matched based on age and gender.

Cohort B - no history of cSCCOther

Participants without a history of squamous cell skin cancer (n=23) will be exposed to acute solar simulated light (SSL). Participants must have sun damage on the forearm, based on a standardized clinical photodamage scale (Hu C, Curiel-Lewandrowski C. Archives of Dermatology, 2011; 147(1):31-36). Each subject will act as his/her own control to minimize inter-subject variability.

Other: Solar Simulated Light

Sites

1 site in 1 country

  • University of Arizona Cancer CenterTucson, Arizona, United States